Literature DB >> 12174359

Hepatitis C and HIV co-infection: a review.

Irena Maier1, George Y Wu.   

Abstract

Co-infection with hepatitis C virus and human immunodeficiency virus is common in certain populations. Among HCV (+) persons, 10 % are also HIV (+), and among HIV (+) persons, 25 % are also HCV (+). Many studies have shown that in intravenous drug users, co-infection prevalence can be as high as 90-95 %. There is increasing evidence supporting the concept that people infected with HIV have a much more rapid course of their hepatitis C infection. Treatment of co-infection is often challenging because highly active anti-retroviral therapy (HAART) therapy is frequently hepatotoxic, especially in the presence of HCV. The purpose of this review is to describe the effects that HIV has on hepatitis C, the effects that hepatitis C has on HIV, and the treatment options in this challenging population.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12174359      PMCID: PMC4656301          DOI: 10.3748/wjg.v8.i4.577

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

1.  Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection.

Authors:  D T Dieterich
Journal:  Am J Med       Date:  1999-12-27       Impact factor: 4.965

2.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.

Authors:  M S Sulkowski; D L Thomas; R E Chaisson; R D Moore
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

3.  Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin.

Authors:  K Stark; E Schreier; R Müller; D Wirth; G Driesel; U Bienzle
Journal:  Scand J Infect Dis       Date:  1995

4.  Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group.

Authors:  V Soriano; J García-Samaniego; R Bravo; J González; A Castro; J Castilla; P Martínez-Odriozola; M Colmenero; E Carballo; D Suárez; F J Rodríguez-Piñero; A Moreno; J del Romero; J Pedreira; J González-Lahoz
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

5.  Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis.

Authors:  B Soto; A Sánchez-Quijano; L Rodrigo; J A del Olmo; M García-Bengoechea; J Hernández-Quero; C Rey; M A Abad; M Rodríguez; M Sales Gilabert; F González; P Mirón; A Caruz; F Relimpio; R Torronteras; M Leal; E Lissen
Journal:  J Hepatol       Date:  1997-01       Impact factor: 25.083

6.  Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study. French Multicenter Study Group.

Authors:  X Causse; J L Payen; J Izopet; G Babany; M F Girardin
Journal:  J Hepatol       Date:  2000-06       Impact factor: 25.083

7.  Management issues in patients coinfected with hepatitis C virus and HIV.

Authors:  Maurizio Bonacini
Journal:  AIDS Read       Date:  2002-01

8.  Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Authors:  M E Eyster; H J Alter; L M Aledort; S Quan; A Hatzakis; J J Goedert
Journal:  Ann Intern Med       Date:  1991-11-15       Impact factor: 25.391

9.  Increased transmission of vertical hepatitis C virus (HCV) infection to human immunodeficiency virus (HIV)-infected infants of HIV- and HCV-coinfected women.

Authors:  V Papaevangelou; H Pollack; G Rochford; R Kokka; Z Hou; D Chernoff; B Hanna; K Krasinski; W Borkowsky
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

10.  Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users.

Authors:  S Pol; B Lamorthe; N T Thi; V Thiers; F Carnot; H Zylberberg; P Berthelot; C Bréchot; B Nalpas
Journal:  J Hepatol       Date:  1998-06       Impact factor: 25.083

View more
  29 in total

Review 1.  Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS.

Authors:  L Degenhardt; W Hall; M Warner-Smith
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

2.  Triple positivity of HBsAg, anti-HCV antibody, and HIV and their influence on CD4+ lymphocyte levels in the highly HIV infected population of Abeokuta, Nigeria.

Authors:  Sandra Olukemi Ogwu-Richard; David Ajiboye Ojo; Olusola Abiodun Akingbade; Iheanyi Omezuruike Okonko
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

3.  N-acetyl cysteine therapy in acute viral hepatitis.

Authors:  Huseyin Gunduz; Oguz Karabay; Ali Tamer; Resat Ozaras; Ali Mert; Omer Fehmi Tabak
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

Review 4.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

5.  Effect of HIV on liver fibrosis among HCV-infected African Americans.

Authors:  D Silver; G Karnik; A Osinusi; R Silk; L Stabinski; L Doonquah; S Henn; G Teferi; H Masur; S Kottilil; D Fishbein
Journal:  Clin Infect Dis       Date:  2013-02-01       Impact factor: 9.079

6.  Increased Immune Response Variability during Simultaneous Viral Coinfection Leads to Unpredictability in CD8 T Cell Immunity and Pathogenesis.

Authors:  Laurie L Kenney; Markus Cornberg; Alex T Chen; Sebastien Emonet; Juan Carlos de la Torre; Liisa K Selin
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

7.  Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.S.

Authors:  Emily Faye White; Richard S Garfein; Kimberly C Brouwer; Remedios Lozada; Rebeca Ramos; Michelle Firestone-Cruz; Saida G Pérez; Carlos Magis-Rodríguez; Carlos J Conde-Glez; Steffanie A Strathdee
Journal:  Salud Publica Mex       Date:  2007 May-Jun

Review 8.  Liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: Diagnostic methods and clinical impact.

Authors:  Caterina Sagnelli; Salvatore Martini; Mariantonietta Pisaturo; Giuseppe Pasquale; Margherita Macera; Rosa Zampino; Nicola Coppola; Evangelista Sagnelli
Journal:  World J Hepatol       Date:  2015-10-28

9.  Factors associated with liver biopsy performance in HCV-HIV coinfected injecting drug users with HCV viremia: results from a five-year longitudinal assessment.

Authors:  Dominique Rey; Maria-Patrizia Carrieri; Bruno Spire; Sandrine Loubière; Pierre Dellamonica; Hervé Gallais; Gilles-Patrice Cassuto; Jean-Albert Gastaut; Yolande Obadia
Journal:  J Urban Health       Date:  2004-03       Impact factor: 3.671

10.  Sequence evolution of putative cytotoxic T cell epitopes in NS3 region of hepatitis C virus.

Authors:  Hua-Zhang Guo; Ying Yin; Wen-Liang Wang; Chuan-Shan Zhang; Tao Wang; Zhe Wang; Jing Zhang; Hong Cheng; Hai-Tao Wang
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.